PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Researchers discover new type of memory B cell that remembers allergies

The cell could be a target for new immunotherapies for the chronic disease.

Researchers from McMaster University and the pharmaceutical company ALK-Abello have discovered a new type of cell that remembers allergies.

Published in Science Translational Medicine, the new discovery could lead to new immunotherapies to treat allergies.

B cells are a type of immune cell that produces antibodies that help fight off infections. However, they can also cause allergies, a common chronic disease.

The new cell, type-2 memory B cell (MBC2), contains “unique characteristics and a unique gene signature that has not been described before,” explained Josh Koenig, assistant professor, department of medicine, McMaster University.

Because of this cell, the immune system will remember the allergy and will create more of the antibodies that make the body allergic the more it encounters it.

Researchers created tetramers, a fluorescent molecule, using allergens including Birch pollen and peanuts to locate difficult-to-find memory B cells.

The team then further leveraged samples gathered from ALK clinical trials with tablet sublingual immunotherapy, which allows for sequencing large amounts of IgE, a type of antibody that triggers allergic reactions and produces B cells.

Koenig said: “We found allergic people had this memory B cell against their allergen, but non-allergic people had very few, if any.”

Researchers were able to discover a connection between MBC2 and IgE using cutting-edge technology, including single-cell transcriptomics and deep sequencing of antibody gene repertoires on clinical trial samples, to reveal the source of the allergy in MBC2.

The new discovery offers a new target for scientists and researchers to treat allergies, which could potentially lead to new therapeutics.

Kelly Burton, postdoctoral fellow, Standford University who co-led the research, explained that there are two possible therapeutic approaches: “The first is targeting those MBC2s and eliminating them from an allergic person” and the second is “changing their function and [having] them do something that’s not going to be ultimately harmful when the individual is exposed to the allergen”.

“These are the types of discoveries that you really need to make in order to develop the right therapeutics to block the right cells to stop the disease,” added Koenig.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026